1115 related articles for article (PubMed ID: 29233903)
1. Clinical Significance of PD-L1
Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
[TBL] [Abstract][Full Text] [Related]
2. Separation of plasma-derived exosomes into CD3
Theodoraki MN; Hoffmann TK; Whiteside TL
Clin Exp Immunol; 2018 Jun; 192(3):271-283. PubMed ID: 29431869
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
4. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
[TBL] [Abstract][Full Text] [Related]
5. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma.
Malm IJ; Bruno TC; Fu J; Zeng Q; Taube JM; Westra W; Pardoll D; Drake CG; Kim YJ
Head Neck; 2015 Aug; 37(8):1088-95. PubMed ID: 24710745
[TBL] [Abstract][Full Text] [Related]
6. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.
Ludwig S; Floros T; Theodoraki MN; Hong CS; Jackson EK; Lang S; Whiteside TL
Clin Cancer Res; 2017 Aug; 23(16):4843-4854. PubMed ID: 28400428
[No Abstract] [Full Text] [Related]
11. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
14. CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity.
Theodoraki MN; Matsumoto A; Beccard I; Hoffmann TK; Whiteside TL
Oncoimmunology; 2020; 9(1):1747732. PubMed ID: 32313730
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for head and neck cancers: an update and future perspectives.
Doescher J; Laban S; Schuler PJ; Brunner C; Hoffmann TK
Immunotherapy; 2019 May; 11(7):561-564. PubMed ID: 30943860
[No Abstract] [Full Text] [Related]
16. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
17. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
18. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.
Lee Y; Shin JH; Longmire M; Wang H; Kohrt HE; Chang HY; Sunwoo JB
Clin Cancer Res; 2016 Jul; 22(14):3571-81. PubMed ID: 26864211
[TBL] [Abstract][Full Text] [Related]
19. Reactive glia promote development of CD103
Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
[TBL] [Abstract][Full Text] [Related]
20. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]